MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00415-023-11925-6

Медицинская библиотека · Journal of neurology · 2023

Myasthenia gravis treatment in the elderly presents with a significant iatrogenic risk: a multicentric retrospective study.

Chanson Jean-Baptiste, Bouhour Françoise, Aubé-Nathier Anne-Catherine, Mallaret Martial, Vial Christophe, Hacquard Aurélien, Petiot Philippe, Spinazzi Marco, Nadaj-Pakleza Aleksandra, Echaniz-Laguna Andoni

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Myasthenia gravis (MG) is an autoimmune disease treated with acetylcholinesterase inhibitors and immunosuppressant/immunomodulatory drugs. MG is frequently diagnosed in elderly patients, a fragile population in which treatment adverse effects (TAE) have not been evaluated until now.

METHODS

We retrospectively analysed the files of all MG patients with disease onset after age 70 years in four French University Hospitals, including clinical, electrophysiological, biological, and treatment data, with an emphasis on TAE. MG outcomes were assessed using the Myasthenia Gravis Foundation of America (MGFA) status scale.

RESULTS

We included 138 patients (59% of men) with a mean follow-up of 4.5 years (range 1-19). Mean age at diagnosis was 78 years (70-93). Anti-acetylcholine receptor antibodies were found in 87% of cases, electrophysiological abnormalities in 82%, and thymoma in 10%. MG outcome was good in a majority of cases, with 76% of treated patients presenting with alleviated symptoms at follow-up. TAE were observed in 41% of patients, including severe TAE in 14% of cases. Seven patients (5.1%) died, including four (2.9%) from MG-related respiratory failure, and three (2.2%) from MG treatment-related complications, i.e., sepsis in 2 cases and brain toxoplasmosis in 1 case. TAE were observed in 53% of patients treated with azathioprine, 23% of patients treated with corticosteroids, and 15% of patients treated with mycophenolate mofetil.

CONCLUSIONS

This retrospective study demonstrates MG in the elderly presents with a significant iatrogenic risk, including fatal immunosuppressant-related infections.

Для цитирования: Chanson Jean-Baptiste, Bouhour Françoise, Aubé-Nathier Anne-Catherine, Mallaret Martial, Vial Christophe, Hacquard Aurélien, Petiot Philippe, Spinazzi Marco, Nadaj-Pakleza Aleksandra, Echaniz-Laguna Andoni. Myasthenia gravis treatment in the elderly presents with a significant iatrogenic risk: a multicentric retrospective study.. Journal of neurology. 2023. DOI: 10.1007/s00415-023-11925-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.